
[Federal Register Volume 79, Number 76 (Monday, April 21, 2014)]
[Notices]
[Page 22148]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-08968]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0001]


Request for Notification From Industry Organizations Interested 
in Participating in the Selection Process for Nonvoting Industry 
Representatives; Reopening of Notification Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; reopening of comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is reopening the period 
for industry organizations interested in participating in the selection 
of nonvoting industry representatives to represent the interests of the 
pharmaceutical manufacturing industry and the pharmacy compounding 
industry on the Pharmacy Compounding Advisory Committee for the Center 
for Drug Evaluation and Research to notify FDA of such interest. FDA 
announced a request for notification of interest in selection of 
industry representatives and for nominations in the Federal Register on 
January 13, 2014. This notice requested industry organizations that 
were interested in participation in the selection process to notify FDA 
in writing by February 12, 2014, and stated that nominations would be 
accepted for the two nonvoting vacancies by the same date. Industry 
organizations that did not notify FDA by the deadline of their interest 
in participating in the selection of nonvoting pharmacy compounding and 
pharmaceutical manufacturing industry representatives have now 
expressed interest in participating. Therefore, FDA is reopening the 
notification period for an additional two weeks so that any interested 
industry organizations wanting to participate can notify the Agency of 
their interest.

DATES: Any industry organization interested in participating in the 
selection of appropriate nonvoting members to represent the interests 
of the pharmacy compounding industry and the pharmaceutical 
manufacturing industry on the Pharmacy Compounding Advisory Committee 
should send a letter stating the interest to FDA by May 5, 2014, for 
the vacancies announced in the Federal Register on January 13, 2014 (79 
FR 2177).

ADDRESSES: All letters of interest should be submitted electronically 
to PCAC@fda.hhs.govmailto:, or in writing by mail to Jayne E. Peterson, 
Center for Drug Evaluation and Research, Food and Drug Administration, 
10903 New Hampshire Avenue, Bldg. 31, Rm. 2417, Silver Spring, MD 
20993.

FOR FURTHER INFORMATION CONTACT: Jayne E. Peterson, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993, 301-796-
9001, FAX: 301-847-8533, email: PCAC@fda.hhs.gov.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: April 15, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-08968 Filed 4-18-14; 8:45 am]
BILLING CODE 4160-01-P


